Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02840461 · ClinicalTrials.gov registry record · Phase 3
Clinical Endpoint Study of Ivermectin 1% Cream
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
NCT02840461 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 630 participants.
The verdict
NCT02840461, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.
Interventions
- DRUG Ivermectin Cream, 1%
- DRUG Placebo/Vehicle cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02840461
The ClinicalTrials.gov registry entry for NCT02840461 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ivermectin Cream, 1% is the first listed.
NCT02840461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02840461 about?
NCT02840461 is a clinical study titled "Clinical Endpoint Study of Ivermectin 1% Cream". A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustula...
What is the current status of trial NCT02840461?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2016-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02840461?
The interventions under investigation include: Ivermectin Cream, 1% (DRUG), Placebo/Vehicle cream (DRUG).
Who is sponsoring clinical trial NCT02840461?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.